Drug Profile
Research programme: follicle stimulating hormone - Protalix BioTherapeutics
Alternative Names: PRX-111; PRX-113Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Protalix Biotherapeutics
- Developer Protalix BioTherapeutics
- Class Hormones
- Mechanism of Action Hormone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infertility
Most Recent Events
- 28 May 2018 No recent reports of development identified for research development in Infertility in Israel
- 04 Jul 2014 Early research is ongoing in Israel